Samsung Bioepis Confirms Consistent Efficacy of Osteoporosis Biosimilar Obodence Across Diverse Patient Populations
Key Insights
Samsung Bioepis (search) presented subgroup analysis data from its global phase 3 trial of Obodence at the World Congress on Osteoporosis, demonstrating consistent therapeutic efficacy across diverse patient populations.
The analysis of 456 postmenopausal women with osteoporosis showed that demographic and disease-related factors did not affect treatment efficacy when comparing Obodence to its reference product Prolia.
Both drugs demonstrated consistent bone mineral density improvements at lumbar spine, total hip, and femoral neck after 12 months of treatment, reaffirming their biological similarity.
Samsung Bioepis (search) has presented compelling follow-up data from its global phase 3 clinical trial of Obodence, an osteoporosis biosimilar, demonstrating consistent therapeutic efficacy across diverse patient populations. The company announced the subgroup analysis results at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases held in Prague from Thursday to Sunday.
Clinical Trial Analysis Confirms Biological Similarity
The subgroup analysis evaluated 456 postmenopausal women with osteoporosis who participated in the global phase 3 trial. Researchers specifically assessed how demographic characteristics, including age and body mass index, as well as disease-related factors such as fracture history, affect treatment efficacy between Obodence and its reference product, Prolia.
Samsung Bioepis (search) analyzed percentage changes from baseline in bone mineral density at three critical sites: the lumbar spine, total hip, and femoral neck, measured 12 months after treatment initiation. The analysis compared treatment effects before and after administration of both Obodence and Prolia.
Consistent Efficacy Across Patient Subgroups
The results demonstrated that even after accounting for demographic and disease-related variables, both drugs showed consistent efficacy across all subgroups. This finding reaffirms the biological similarity between Obodence and Prolia that was initially established in the phase 3 trial results.
"Through the latest analysis, we were able to reaffirm Obodence's consistent therapeutic efficacy across diverse patient populations," said Shin Dong-hoon, executive vice president at Samsung Bioepis (search). "We will continue to strengthen our research and development capabilities to expand access to high-quality biologics based on scientific evidence."
Market Position and Commercial Strategy
Prolia, developed by Amgen, represents a significant market opportunity with global revenue of $4.41 billion (6.4 trillion won) in 2025, including 144.6 billion won in the Korean market. Samsung Bioepis (search) launched Obodence in Korea in July 2024 and has been implementing a multi-faceted global expansion strategy.
The company is expanding its market presence through various channels: supplying the drug in the United States through private label arrangements with pharmacy benefit managers, directly marketing in Europe, and partnering with Hanmi Pharmaceutical for joint sales in Korea. This diversified approach positions Samsung Bioepis (search) to capture market share across multiple regions while leveraging different distribution models suited to local market conditions.